NIVFW NASDAQ

NewGenIvf Group Limited operates as an investment holding company specializing in providing assisted reproductive technologies (ART) for couples and individuals seeking fertility solutions. The company extends its operations across Thailand, Cambodia, Hong Kong, and Kyrgyzstan. Its comprehensive suite of fertility treatments includes fundamental procedures such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and embryo culture. NewGenIvf also offers crucial diagnostic and preparatory services like hormonal blood tests, screenings for infectious diseases, chromosome analysis, and hysteroscopy. Additionally, the company provides specialized sperm services, encompassing analysis, sorting, washing, and cryopreservation, alongside oocyte (egg) freezing. Beyond these core medical services, NewGenIvf facilitates surrogacy arrangements, offering essential ancillary care for surrogate mothers, including routine health check-ups, nutritional supplements, and prescribed medications. To further enhance the patient journey, the company delivers a range of supplementary services such as dietary guidance, psychological counseling, acupuncture, and professional translation interpreters. These specialized medical and support services are delivered through the company's network of dedicated clinics. Founded in 2010, NewGenIvf Group Limited is headquartered in Bangkok, Thailand.